Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (infliximab-abda) subsequently launched in July 2017. Waves 1 and 2 of this series track Inflectra’s awareness and uptake since launch, while Wave 3 also incorporates Renflexis. Along with awareness, familiarity, and perceptions of biosimilars, our research explores the drivers and barriers behind uptake of both Inflectra and Renflexis. Promotional efforts are also explored, as well as prescriber and nonprescriber profiles, and benchmarking comparisons against other available biosimilars, to better understand the dynamics of the U.S. biosimilars market.
- Are U.S. physicians aware of Inflectra and Renflexis?
- What are the drivers to prescribing an infliximab biosimilar? What is the level of Inflectra and Renflexis use, and how is that changing over time?
- Are physicians’ opinions of biosimilars changing?
- Have physicians experienced pressures to prescribe Inflectra or Renflexis to patients?
- What promotional messages are sales representatives employing for Inflectra, Renflexis, and Remicade?
- How does formulary placement of Inflectra and Renflexis compare with Remicade, and does this change over time?
- Markets covered: United States.
- Primary research: Survey of 92 U.S. rheumatologists, gastroenterologists, and dermatologists.
Key Companies Mentioned:
- Johnson & Johnson/Janssen.
- Merck & Co.
- Samsung Bioepis.
Key Drugs Mentioned:
- Remicade (infliximab).
- Inflectra (infliximab-dyyb).
- Renflexis (infliximab-abda).
- Enbrel (etanercept).
- Humira (adalimumab).